Pedro Cahn
机构：Fundación Huésped, Hospital San Juan de Dios · ORCID：0000-0002-9381-1931
发表论文 367 篇 · 总被引 19057 次 · h-index 63
代表论文
- Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (2024 · New England Journal of Medicine · 被引 256)
- Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial (2025 · Clinical Infectious Diseases · 被引 12)
- Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies (2024 · AIDS Research and Therapy · 被引 11)
- Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE Study (2025 · Clinical Infectious Diseases · 被引 9)
- Transcriptome and microbiome-immune changes across preinvasive and invasive anal cancer lesions (2024 · JCI Insight · 被引 5)
- Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trial (2025 · The Lancet HIV · 被引 3)